INVO Fertility, Inc. (IVF) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

INVO Fertility, Inc. (IVF) Healthcare & Pipeline Overview

INVO Fertility, Inc. is a revenue-generating fertility business focused on developing clinical-stage assets in oncology and autoimmune diseases. Headquartered in Sarasota, FL, the company operates within the medical devices industry, offering a unique approach to fertility solutions and exploring opportunities in broader healthcare sectors.

What Is the Investment Thesis for IVF?

INVO Fertility presents a unique investment proposition within the fertility and medical device sectors. The company's INVOcell technology offers a potentially disruptive approach to fertility treatment, providing a more accessible and affordable option compared to traditional IVF. With a gross margin of 39.2%, there is potential for profitability as the company scales its operations. Key growth catalysts include expanding the adoption of INVOcell in existing markets and penetrating new geographic regions. However, the company's negative profit margin of -417.0% and a market capitalization of $1.72M indicate significant financial risks and reliance on future funding. The high beta of 2.67 suggests high volatility relative to the market. Success hinges on effective commercialization of INVOcell and progress in its oncology and autoimmune disease assets.

Based on FMP financials and quantitative analysis

IVF Key Highlights

Gross Margin of 39.2% indicates potential for profitability with increased scale.

• Focus on INVOcell technology offers a potentially disruptive approach to fertility treatment.
• Operations in the fertility sector address a significant and growing market need.
• Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
• Headquartered in Sarasota, FL, with a team of approximately 30 employees.

Who Are IVF's Competitors?

IVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IVF's Key Strengths?

Proprietary INVOcell technology offers a differentiated approach to fertility treatment.

• Focus on affordability and accessibility expands the potential market for fertility services.
• Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
• Established partnerships with fertility clinics and healthcare providers.

What Are IVF's Weaknesses?

Negative profit margin indicates financial instability.

• Limited market capitalization reflects investor concerns.
• High beta suggests high volatility relative to the market.
• Reliance on future funding to support operations and development.

What Could Drive IVF Stock Higher?

Regulatory approvals for clinical-stage assets in oncology and autoimmune diseases could drive significant value.

• Expansion of INVOcell adoption in existing and new markets will drive revenue growth.
• Strategic partnerships with pharmaceutical companies and research institutions can accelerate development and commercialization efforts.

What Are the Key Risks for IVF?

Financial-distress signal — its Altman Z-Score of -5.74 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-47.4%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Competition from established IVF providers and other fertility technology companies could limit market share.
• Regulatory hurdles and changing healthcare policies could impact the adoption of INVOcell and the development of new therapies.
• Negative profit margin and reliance on future funding pose financial risks.
• Setbacks in clinical trials for oncology and autoimmune disease assets could delay or halt development.

What Are the Growth Opportunities for IVF?

• Expanding INVOcell Adoption: A significant growth opportunity lies in increasing the adoption of INVOcell technology within existing markets. This involves educating potential patients and healthcare providers about the benefits of INVOcell compared to traditional IVF, focusing on its affordability and more natural approach. Success in this area would drive revenue growth and market share.
• Geographic Expansion: INVO Fertility can pursue growth by expanding its geographic presence, particularly in underserved markets where access to fertility treatment is limited. This could involve establishing partnerships with local clinics and healthcare providers to offer INVOcell as a viable option. Entering new markets requires careful consideration of regulatory requirements and cultural factors. The timeline for geographic expansion depends on securing necessary approvals and establishing operational infrastructure.
• Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate INVO Fertility's growth. These partnerships can provide access to new technologies, funding, and market channels. Collaborations can also enhance the company's research and development efforts in oncology and autoimmune diseases. The success of partnerships depends on aligning strategic goals and establishing mutually beneficial terms.
• Development of Oncology and Autoimmune Assets: INVO Fertility's development of clinical-stage assets in oncology and autoimmune diseases represents a significant growth opportunity. Advancing these assets through clinical trials and securing regulatory approvals could lead to the commercialization of new therapies and generate substantial revenue. This strategy diversifies the company's portfolio and reduces its reliance on the fertility market. The timeline for developing these assets depends on the progress of clinical trials and regulatory review processes.
• Enhancing Marketing and Sales Efforts: Strengthening marketing and sales efforts is crucial for driving awareness and adoption of INVOcell technology. This involves developing targeted marketing campaigns, participating in industry conferences, and building relationships with key opinion leaders. Effective marketing and sales strategies can increase patient referrals and drive revenue growth. The timeline for implementing these strategies depends on allocating sufficient resources and developing a comprehensive marketing plan.

What Are IVF's Competitive Advantages?

• Proprietary INVOcell technology offers a differentiated approach to fertility treatment.
• Focus on affordability and accessibility expands the potential market for fertility services.
• Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
• Established partnerships with fertility clinics and healthcare providers.

What Does IVF Do?

Founded on January 5, 2007, INVO Fertility, Inc. is dedicated to providing accessible and innovative fertility solutions. The company operates as a revenue-generating fertility business, primarily focusing on its INVOcell technology, an innovative intravaginal culture (IVC) system. INVOcell is designed to offer a more natural and affordable fertility treatment option compared to traditional in-vitro fertilization (IVF). INVO Fertility aims to expand access to fertility care, particularly in underserved markets. Beyond fertility, INVO Fertility is also involved in the development of clinical-stage assets in oncology and autoimmune diseases, diversifying its portfolio within the healthcare sector. The company is headquartered in Sarasota, FL, and manages its operations with a team of approximately 30 employees.

What Products and Services Does IVF Offer?

• Operates as a revenue-generating fertility business.
• Develops and commercializes the INVOcell system for intravaginal culture (IVC).
• Offers a more affordable and natural alternative to traditional IVF.
• Focuses on expanding access to fertility care.
• Develops clinical-stage assets in oncology and autoimmune diseases.
• Seeks to diversify its healthcare portfolio beyond fertility.

How Does IVF Make Money?

• Generates revenue through the sale of INVOcell devices and related products.
• Partners with fertility clinics to offer INVOcell treatment to patients.
• Potentially generates revenue from the commercialization of oncology and autoimmune disease assets.
• May explore licensing agreements or strategic partnerships to expand market reach.

What Industry Does IVF Operate In?

INVO Fertility operates within the medical devices industry, specifically targeting the fertility sector. The fertility market is driven by increasing rates of infertility, advancements in reproductive technologies, and growing awareness of treatment options. Competition includes established IVF providers and other fertility technology companies. INVO Fertility's INVOcell technology aims to differentiate itself by offering a more accessible and affordable alternative to traditional IVF. The company's expansion into oncology and autoimmune diseases positions it within broader and highly competitive pharmaceutical and biotechnology markets.

Who Are IVF's Key Customers?

• Fertility clinics and healthcare providers.
• Patients seeking fertility treatment.
• Potential partners in the pharmaceutical and biotechnology industries.
• Research institutions involved in oncology and autoimmune disease research.

INVO Fertility, Inc. (IVF) Valuation Context

Valued at $1.72M, IVF is classified as a micro-cap stock. Analyst price targets span from $20.00 to $20.00, with a consensus of $20.00. At the current price of $0.96, that implies approximately 1975% upside potential. Relative to its peer group, IVF's quantitative score of 21/100 is below the peer average of 49/100.

IVF Revenue & Earnings Trend

In Q2 FY2026, IVF generated $2.2M in top-line revenue, marking a sequential increase of 8.0%. The company recorded net income of $889K, with diluted EPS of $0.34. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, IVF averaged $-7.38 in diluted EPS.

Company Profile

INVO Fertility, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Steven Shum. IVF has traded publicly since 2020.

Return on equity for INVO Fertility, Inc. stands at -47.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.5%, showing how much profit it generates from its asset base. A current ratio of 0.71 means current liabilities exceed short-term assets, a liquidity point worth watching.

INVO Fertility, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.74 places it in the distress zone, a signal of elevated financial risk.

INVO Fertility, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 277.3% below estimates on average.

The most recent 7 insider filings for INVO Fertility, Inc. break down as 2 sales and 5 purchases. On net that is roughly 227K shares acquired (about $229K) — insiders putting money in tends to read as conviction.

IVF Financials

IVF Latest News

IVF Analyst Consensus

IVF MoonshotScore

INVO Fertility, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources